ANRS Prevenir cohort
HIV prevention in the Paris Region
Published on 22 July 2024
What is the ANRS Prévenir cohort?
- The ANRS Prévenir cohort is a study being carried out in the Île-de-France region aimed at preventing new HIV infections through the use of pre-exposure prophylaxis (PrEP), which consists, for people not infected with the virus, of daily preventive use of treatments (antiretrovirals) to prevent the acquisition of HIV.
- The study, which began in May 2017, is being conducted by Prof. Jean-Michel Molina’s team (from the infectious and tropical diseases department at Saint-Louis and Lariboisière hospitals, AP-HP and Université Paris Cité), in partnership with the AIDES association.
- The cohort is funded by ANRS MIE and Sidaction.
What is the aim of the cohort?
The main objective of the cohort is to significantly reduce the number of new HIV infections in the region by facilitating access to PrEP, a strategy for preventing HIV infection, for high-risk populations.
To achieve this, the cohort recruited participants who were not infected with HIV but were at high risk of contracting the virus. A total of 3,057 HIV-negative volunteer participants at high risk of HIV infection were included.
The PrEP administered is the antiretroviral treatment combination Tenofovir/emtricitabine TDF/FTC, in accordance with the indications and conditions of use defined by the French Marketing Authorisation (MA), the French National Recommendations and the European MA for medicines.
In brief
Principal investigator
Pr. Jean-michel Molina
Co-investigators
Pr. Jade Ghosn, Mme Daniela Rojas (AIDES/ Coalition plus)
Pathology
Prevention of HIV infection
Sponsoship
ANRS MIE
The ANRS Prévenir cohort is essential to the development of effective public health policies, making it possible to curb the spread of HIV in France and to support the most vulnerable populations with appropriate and accessible means of prevention.
Latest project news
Several studies have been set up as part of the ANRS Prévenir research programme and major publications have been produced based on the cohort:
- The ANRS-Prévenir study published in 2022, which showed that on-demand PrEP was as effective as continuous PrEP, with a low incidence of HIV-1 on PrEP that did not differ between participants using daily PrEP and those using on-demand PrEP.
The ANRS DOXYVAC trial, conducted as part of the PREVENIR cohort, demonstrated the post-exposure efficacy of an antibiotic, doxycycline, in reducing the occurrence of STIs (see press release below)
Scientific publications
- Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D; ANRS 174 DOXYVAC Study Group. Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236-6
- Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine. Chawki S, Goldwirt L, Mouhebb ME, Gabassi A, Taouk M, Bichard I, Loze B, Amara A, Brand R, Siegel A, McGowan I, Costagliola D, Assoumou L, Molina JM, Delaugerre C; ANRS PREVENIR Study group. 2024 Mar 15;38(4):455-464.
- Perception of PrEP-related stigma in PrEP users: Results from the ANRS-PREVENIR Protiere C, Sagaon-Teyssier L, Donadille C, Sow A, Gaubert G, Girard G, Mora M, Assoumou L, Beniguel L, Michels D, Ghosn J, Costagliola D, Rojas Castro D, Molina JM, Spire B; ANRS PREVENIR Study-Group. HIV Med. 2023 Aug;24(8):938-945
- Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR Liegeon G, Assoumou L, Ghosn J, El Mouhebb M, Palich R, Palacios C, Slama L, Surgers L, Genin M, Beniguel L, Goldwirt L, Duvivier C, Rojas Castro D, Costagliola D, Molina JM. J Antimicrob Chemother. 2022 Nov 28;77(12):3427-3435
- Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D; ANRS PREVENIR Study Group. Lancet HIV. 2022 Aug;9(8):e554-e562.
- Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts. Delaugerre C, Assoumou L, Maylin S, Minier M, Gabassi A, Genin M, Beniguel L, Ghosn J, de Lamballerie X, El Mouhebb M, Costagliola D, Carrat F, Molina JM; PREVENIR and SAPRIS-Sero Study Groups. Open Forum Infect Dis. 2022 Apr 12;9(7):ofac188
- How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR Puppo C, Spire B, Morel S, Génin M, Béniguel L, Costagliola D, Ghosn J, Mabire X, Molina JM, Rojas Castro D, Préau M. AIDS Care. 2020 May;32(sup2):32-39
Acceptability of PreP in Cambodia in 2024
An unprecedented study on key populations that are particularly vulnerable to HIV
24 May 2024